Chemours has completed its planned procedures with respect to an internal review that it first announced on 29 February. This essentially confirmed the details revealed in an interim report on 7 March. More will be published in the compensation discussion and analysis in the proxy statement for the 2024 annual meeting.

The board of Chemours has put CEO Mark Newman, CFO Jonathan Lock and principal accounting officer Camela Wisel on administrative leave pending the completion of an internal review by independent counsel that the board’s audit committee is overseeing.